Aims: Reduced heart rate variability (HRV) and increased heart rate (HR) are associated with cardiovascular (CV) mortality. In the Liraglutide Effect and Action in Diabetes outcome trial, it was demonstrated a lower rate of CV events in type 2 diabetes (T2D) patients treated with liraglutide compared to placebo. We aimed to investigate the effects of liraglutide compared with glimepiride treatment in T2D patients on the CV risk parameters HR and HRV.
| INTRODUC TI ON
Individuals with type 2 diabetes (T2D) have an increased risk of cardiovascular (CV) complications compared with the general population in which a multitude of risk factors for CV events are involved. 1 Multifactorial intervention against CV risk factors such as hyperlipidaemia, hypertension and hyperglycaemia has a sustained beneficial effect on CV complications. 2 One overlooked diabetes complication is cardiovascular autonomic neuropathy (CAN). 3 Micro-and macrovascular complications resulting from CAN involve damage to the autonomic nerve fibres that innervate the heart and the vessels, which in turn may lead to dysfunctional heart rate (HR) control. A disorder of the automatic nervous system (ANS) reflects an imbalance between the sympathetic and the parasympathetic activity that can be assessed by measuring heart rate variability (HRV), that is the variation between two consecutive heartbeats; the higher the variation, the higher is the parasympathetic activity. Higher parasympathetic activity protects against CV events, whereas low HRV predicts CV events. 
| TRIAL DE S I G N
This post hoc study was an open, assessor-blinded, randomized, controlled, parallel-group trial and a part of a larger study identified as NCT01425580 (www.clinicaltrials.gov). The main results of this study have been published elsewhere. 6 Briefly, T2D patients who had glycated haemoglobin A1c
(HbA1c) of 6.3% -11% (45-97 mmol/mol) were eligible if they had not been previously treated with GLP-1 RA, dipeptidyl peptidase-4 inhibitors or glimepiride. Patients who met these criteria were invited for echocardiographic screening, in which one of the following criteria had to be fulfilled: left ventricle ejection fraction ≤50% or evidence of diastolic dysfunction. The major exclusion criteria were as follows: type 1 diabetes, treatment with glitazones during the previous 6 months, treatment with sulphonylureas in the previous 3 months, insulin treatment within the previous month, heart failure according to the New York Heart Association classification 3-4, past history of atrial fibrillation or flutter, presence of acute myocarditis or significant valvulopathies, uncontrolled hypertension, severe heart conduction disturbances or ventricular tachyarrhythmia within the previous 3 months, unstable angina or myocardial infarction in the previous 8 weeks, estimated glomerular filtration rate <30 mL/min, haemoglobin <90 g/L, BMI >40 kg/ m 2 , severe gastrointestinal disease, history of acute or chronic pancreatitis, malign neoplasia within the last 5 years, current drug or alcohol abuse and pregnancy.
Patients were block-randomized using sealed envelopes to receive either liraglutide or glimepiride during an 18-week treatment period. The initial dose of liraglutide was 0.6 mg (sc), with an up-titration of 0.6 mg every week to a final dose of 1.8 mg per day. The initial dose of the comparator was 2 mg glimepiride with an up-titration of 1 mg every week, reaching a final dose of 4 mg per day. The regional ethics committees at both participating centres reviewed and approved the trial protocol, and the study followed the International
Conference on Harmonization-Good Clinical Practice guidelines. All subjects provided written informed consent before enrolment.
| Twenty-four-hour
Holter monitoring (heart rate, heart rate variability and spectrum analysis) 
| Statistical analysis
Continuous data are presented as mean ± standard deviation (SD) or median with corresponding 1st quartile (Q1) and 3rd quartile (Q3), and categorical data are presented as percentages. 
| RE SULTS
The CONSORT flow chart of the study is provided in Figure 1 . One hundred and five patients were screened, while 43 of these were F I G U R E 1 Flow chart for the study groups. 105 patients were screened, whereas 62 patients were eligible for the study, of these 33 vs 29 were randomized to liraglutide vs glimepiride, respectively. Due to technical hitches and dropouts, there were 29 in the liraglutide vs 24 in the glimepiride group, who were analysed per-protocol, that is full data set Sensitivity analysis (ITT analysis) was also carried out for our end-points.
There was a statistically significant but small difference in HbA1c
and triglycerides observed between groups (Table 1 TA B L E 2 Effects of treatment change (baseline and at 18 weeks of treatment) for heart rate, heart variability and spectrum (frequency) analysis between groups treated with liraglutide vs glimepiride in combination with metformin 
| Heart rate, heart rate variability and spectrum analysis (Fourier)
All data on HR, HRV and spectrum analysis are presented in Table 2 .
Depending on modalities and missing data from pre-and post-treatment 24-hour Holter recordings and owing to technical reasons (see above), there were 53 individuals ( Table 2 and Figure 1 ) included in the final analysis (per-protocol).
At 18 weeks of treatment, there was a persistent increase in diurnal variation in hourly mean HR observed in the liraglutide-treated group ( Figure 2 ). There was an increased mean HR at daytime in the liraglutide-treated group compared with the glimepiride-treated group (Table 2 ). There was a trend for an increased mean HR at nighttime (P = 0.072) and for the 24-hour period (P = 0.079) observed in the liraglutide-treated group compared with the glimepiride-treated group (Table 2) . Sensitivity analysis (ITT analysis) did not change the results (Table 2 ).
In the 24-hour time domain HRV, there were no statistically significant difference in treatment changes observed between groups for any of our variables, that is mean NN, SDDN, SDNN index, SDANN or pNN50% (Table 2 ). This non-significant treatment changes were also demonstrated in the ITT analysis (Table 2 ).
In the spectrum analysis (Fourier), which can reveal changes between sympathetic and parasympathetic activity, no statistically significant treatment change for any of the frequency domain variables, that is VLF, LF, HF and total power were observed between groups (Table 2) . ITT analysis did not change the results.
Since there were significant treatment changes in parameters that may have affected ANS balance, that is glycaemic control, weight and blood pressure, we further did a simple regression analysis between on the one hand HbA1c, systolic BP, diastolic BP and weight, and on the other hand mean HR and SDNN. Coefficient of regression among these parameters and variables of HR, HRV and spectrum analysis is presented in Table 3 . In the liraglutide group, there were statistically significant association between treatment changes in mean NN (P = 0.006) and weight (P = 0.019) against F I G U R E 2 Diurnal variation in hourly mean HR between groups (liraglutide vs glimepiride). Error bars indicate mean ± standard error. Generalized linear mixed model for repeated measures was used to test the difference between the two groups. P * is P-value adjusted for baseline heart rate. BPM; Beats per minute SDNN; and a statistically significant association between treatment changes in LF (P < 0.001) and HF (P < 0.001) against RMSSD (Table 3 ). For the glimepiride group, there was only a significant correlation between treatment changes in LF (P = 0.015) and HF (P < 0.001) against RMSSD (Table 3 ).
| D ISCUSS I ON
In this open parallel study where T2D patients with subclinical heart failure were randomized to an 18-week treatment period with liraglu- and on the other hand regulated by peripheral nervous structures by adrenergic and non-adrenergic stimulation. 11 This contrast clinical studies where a small reduction in blood pressure with a reciprocal small increase in HR frequently is reported 4, [8] [9] [10] and suggested to be secondarily to vasodilatation, that is reflex tachycardia. 15 However, recent reports have revealed GLP-1 R expression in the heart only by the sinoatrial node (SAN) myocytes, 16 whereas GLP-1 RA treatment directly may stimulate SAN to increase HR 17, 18 In the present study, we confirm previous observations, demonstrating an increase in HR due to liraglutide treatment. Patients treated with liraglutide had a persistent increased diurnal variation in hourly mean HR followed by a significant increase in HR for the day- There is an increased risk of premature CV death with more rapid HR 21, 22 Also, low HRV, reflecting an imbalance in ANS, is a predictor of CV events. 23 Despite a small, however significant, increase in HR in the large GLP-1 RA CV outcome studies patients treated with GLP-1 RA are not at higher risk of CV death compared with placebo. 4, [8] [9] [10] In fact, in the LEADER study, patients treated with liraglutide were at lower risk for CV death compared with patients treated with placebo. 4 Recently, it was demonstrated in newly diagnosed overweight T2D patients treated with liraglutide an increased HR concomitant with a reduction in HRV (increased nightly HR and decreased parasympathetic activity).
This effect was independent of weight loss and any improvement in glycaemic control and suggested to be due to changes in sympathovagal balance. 24 This contrasts to the present study results;
although the increase in HR was much the same, we were not able to demonstrate any treatment change in the ANS balance (HRV or spectrum analysis). We cannot exclude that differences in diabetes duration, treatment duration, trial design or comorbidities may explain the difference between studies. One major difference between studies was that patients in the present study were diagnosed with subclinical heart failure (inclusion criteria) and therefore at high risk for CAN. 25 Therefore, our findings cannot be generalized to other than patients with T2D with subclinical heart failure.
Previous studies suggest that GLP-1 RA directly may activate SAN myocytes and increases HR 26 Although receptors for GLP-1 only are expressed by SAN myocytes, there is body of evidence demonstrating physiological action on the heart from GLP-1 R activation. 5 Some of these actions may be mediated through both GLP-1 R-dependent and GLP-1 R-independent pathways 27 ; however, different actions by different GLP-1 RA may also contribute to varying results. 18 T2D patients treated with different GLP-1 RA had an increase in HR (acute and after 12 weeks) that was not explained by changes in sympathetic activity, or a reflex to vasodilation, suggesting direct stimulation of SAN involved. 18 Acute administration of exenatide into healthy overweight men 17 and into T2D patients with heart failure 28 increased HR that not was due to reflex tachycardia, however rather to the involvement of sympathetic action or stimulation of SAN. In another recent study where T2D patients received exenatide extended-release, there was an increase in HR that did not appear to be related to sympathetic influence. 29 In a current study, simple regression However, patients were randomized to one of the treatment groups and data were analysed blinded to minimize further biases.
At baseline, there was a small, however significant, higher HbA1c
and triglycerides concentrations observed in the group allocated to liraglutide. Although, no treatment changes (after 18 weeks)
were observed in these parameters between groups, we cannot entirely role out that this difference might have affected our outcome. As the comparator group were treated with glimepiride, the possibility of hypoglycaemia-induced tachycardia has to be considered. However, there was no severe hypoglycaemic event during the study (no groups) although a numerical (non-significant) higher numbers of mild hypoglycaemia in the glimepiride group was observed. 6 Despite this HR was not increased in pa- 
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